Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide in HIV-1 reservoir elimination
NCT03980665Phase 1Recruiting
- Sponsor
- Guangzhou Eighth People's Hospital
- Start
- Apr 2019
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of arsenic trioxide in human immunodeficiency virus infection (HIV), sponsored by Guangzhou Eighth People's Hospital. Primary endpoint: Incidence of treatment-emergent adverse events at 6 months. Started Apr 2019; status: recruiting.
02
Drugs
arsenic trioxide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03980665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980665.